Schizophrenia drug development may be 'de-risked' with new research tool
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.
Nov 22, 2017